MARK E PRINCE, MD
Medical Practice in Ann Arbor, MI
License number
Michigan 4301068449
Category
Medical Practice
Type
Otolaryngology
Address
Address
1500 Floor Taubman Ctr, Ann Arbor, MI 48109
Phone
(734) 936-8051
(734) 936-2047
(734) 936-2047
Personal information
See more information about MARK E PRINCE at radaris.comName
Address
Phone
6389 Vineyard Ave, Ann Arbor, MI 48108
4052 Broadmoor Ct, Howell, MI 48843
41849 Ladywood Dr, Northville, MI 48168
6389 Vineyard Ave APT 19, Ann Arbor, MI 48108
644 Olde Ivy Ln, Howell, MI 48843
Professional information
Mark E Prince, Ann Arbor MI
Specialties:
Ear, Nose & Throat Doctor
Address:
1500 E Medical Center Dr, Ann Arbor, MI 48109
Education:
Dalhousie University, Faculty of Medicine - Doctor of Medicine*
Queen Elizabeth II Health Sciences Centre - Victoria Building - Residency - Otolaryngology-Head and Neck Surgery*
Queen Elizabeth II Health Sciences Centre - Victoria Building - Residency - Surgery*
Queen Elizabeth II Health Sciences Centre - Victoria Building - Residency - Otolaryngology-Head and Neck Surgery*
Queen Elizabeth II Health Sciences Centre - Victoria Building - Residency - Surgery*
Board certifications:
American Board of Otolaryngology Certification in Otolaryngology*
Mark Prince, Ann Arbor MI
Specialties:
Otolaryngology, Plastic Surgery within the Head & Neck, Surgery, Plastic Surgery Within the Head and Neck
Work:
Va Ann Arbor Healthcare System
2215 Fuller Rd, Ann Arbor, MI 48105
2215 Fuller Rd, Ann Arbor, MI 48105
Education:
Dalhousie University Faculty Of Medicine (1988)
Dr. Mark E Prince, Ann Arbor MI - MD (Doctor of Medicine)
Specialties:
Ear, Nose, and Throat, Orthopedic Head & Neck Surgery, Orthopedic Surgery
Address:
University Michigan Med Ctr OTO
1500 E Medical Center Dr #Suite 1904&2560, Ann Arbor 48109
(734) 936-8051 (Phone)
1500 E Medical Center Dr #Suite 1904&2560, Ann Arbor 48109
(734) 936-8051 (Phone)
Languages:
English
Hospitals:
University Michigan Med Ctr OTO
1500 E Medical Center Dr #Suite 1904&2560, Ann Arbor 48109
Chelsea Community Hospital
775 South Main St, Chelsea 48118
University of Michigan Health System
1500 East Medical Center Dr SPC 5474, Ann Arbor 48109
1500 E Medical Center Dr #Suite 1904&2560, Ann Arbor 48109
Chelsea Community Hospital
775 South Main St, Chelsea 48118
University of Michigan Health System
1500 East Medical Center Dr SPC 5474, Ann Arbor 48109
Education:
Medical School
Dalhousie University Faculty Of Medicine
Graduated: 1988
Dalhousie University
Graduated: 1989
Graduated: 1992
University Of Michigan
Graduated: 1998
Dalhousie University Faculty Of Medicine
Graduated: 1988
Dalhousie University
Graduated: 1989
Graduated: 1992
University Of Michigan
Graduated: 1998
Compositions And Methods For Treating And Diagnosing Cancer
US Patent:
2014003, Jan 30, 2014
Filed:
Jul 11, 2013
Appl. No.:
13/939861
Inventors:
Tim Hoey - Hillsborough CA, US
Xinhao Wang - Freemont CA, US
Scott Dylla - Mountain View CA, US
Austin Gurney - San Francisco CA, US
Piero Dalerba - Palo Alto CA, US
Grace Chen - Howell MI, US
Mark Prince - Ann Arbor MI, US
Xinhao Wang - Freemont CA, US
Scott Dylla - Mountain View CA, US
Austin Gurney - San Francisco CA, US
Piero Dalerba - Palo Alto CA, US
Grace Chen - Howell MI, US
Mark Prince - Ann Arbor MI, US
Assignee:
The Regents of the University of Michigan - Ann Arbor MI
International Classification:
C12N 5/095
US Classification:
4351739, 435325
Abstract:
The present invention relates to compositions and methods for characterizing, treating and diagnosing cancer. In particular, the present invention provides a cancer stem cell profile, as well as novel stem cell cancer markers useful for the diagnosis, characterization, prognosis and treatment of cancer and in particular the targeting of solid tumor stem cells.
Compositions And Methods For Treating And Diagnosing Cancer
US Patent:
2010016, Jul 1, 2010
Filed:
Dec 31, 2009
Appl. No.:
12/650873
Inventors:
Michael F. Clarke - Menlo Park CA, US
Tim Hoey - Hillsborough CA, US
Xinhao Wang - Freemont CA, US
Scott Dylla - Mountain View CA, US
Austin Gurney - San Francisco CA, US
Piero Dalerba - Palo Alto CA, US
Grace Chen - Howell MI, US
Mark Prince - Ann Arbor MI, US
Tim Hoey - Hillsborough CA, US
Xinhao Wang - Freemont CA, US
Scott Dylla - Mountain View CA, US
Austin Gurney - San Francisco CA, US
Piero Dalerba - Palo Alto CA, US
Grace Chen - Howell MI, US
Mark Prince - Ann Arbor MI, US
Assignee:
THE REGENTS OF THE UNIVERSITY OF MICHIGAN - Ann Arbor MI
International Classification:
A01K 67/00, C12N 5/00
US Classification:
800 10, 435325
Abstract:
The present invention relates to compositions and methods for characterizing, treating and diagnosing cancer. In particular, the present invention provides a cancer stem cell profile, as well as novel stem cell cancer markers useful for the diagnosis, characterization, prognosis and treatment of cancer and in particular the targeting of solid tumor stem cells.
Compositions And Methods For Treating And Diagnosing Cancer
US Patent:
7723112, May 25, 2010
Filed:
Oct 31, 2006
Appl. No.:
11/591019
Inventors:
Michael F. Clarke - Palo Alto CA, US
Tim Hoey - Hillsborough CA, US
Xinhao Wang - Freemont CA, US
Scott Dylla - Mountain View CA, US
Austin Gurney - San Francisco CA, US
Piero Dalerba - Palo Alto CA, US
Mark Prince - Ann Arbor MI, US
Grace Chen - Howell MI, US
Tim Hoey - Hillsborough CA, US
Xinhao Wang - Freemont CA, US
Scott Dylla - Mountain View CA, US
Austin Gurney - San Francisco CA, US
Piero Dalerba - Palo Alto CA, US
Mark Prince - Ann Arbor MI, US
Grace Chen - Howell MI, US
Assignee:
The Regents of the University of Michigan - Ann Arbor MI
OncoMed Pharmaceuticals, Inc. - Redwood City CA
OncoMed Pharmaceuticals, Inc. - Redwood City CA
International Classification:
G01N 33/53
US Classification:
435971, 435 71, 435325, 435968
Abstract:
The present invention relates to compositions and methods for characterizing, treating and diagnosing cancer. In particular, the present invention provides a cancer stem cell profile, as well as novel stem cell cancer markers useful for the diagnosis, characterization, prognosis and treatment of cancer and in particular the targeting of solid tumor stem cells.